对饮食中的生物活性成分的抗血栓作用的新见解
Nidesha Randeni1, Jinhai Luo1, Baojun Xu1
1Food Science and Technology Program, Department of Life Sciences, Beijing Normal-Hong Kong Baptist University, Zhuhai, Guangdong 519087, China. baojunxu@uic.edu.cn.
Food & function
|October 24, 2025
概括
饮食中的生物活性化合物通过向血小板聚合和凝固,在预防和治疗血栓性疾病方面表现有前途. 需要进一步的临床试验来证实对管理这些全球健康威胁的有效性和安全性.
科学领域:
- 营养科学 营养科学
- 生物化学 生化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 血栓性疾病是全球主要的健康挑战.
- 饮食中的生物活性化合物正在研究它们的治疗潜力.
- 来源包括植物,海洋生物和微生物,提供多种化合物,如多和omega-3脂肪酸.
研究的目的:
- 审查饮食中的生物活性化合物可以减轻血栓形成的机制.
- 探索各种生物活性化合物在预防和管理血栓性疾病方面的潜力.
- 突出未来研究领域,包括临床试验和分子机制.
主要方法:
- 临床前和临床研究的文献综述.
- 对食中生物活性化合物的作用机制的分析.
- 探索生物活性化合物的来源和类型.
主要成果:
- 饮食中的化合物调节血小板聚合,凝血级联和纤维素分解.
- 机制包括改善内皮功能,减少炎症和氧化应激.
- 临床前和一些临床数据令人鼓舞,但需要进一步验证.
结论:
- 饮食中的生物活性物质为治疗血栓性疾病提供了一个有希望的途径.
- 更强大的临床试验对于确定疗效,安全性和最佳剂量至关重要.
- 未来的研究应该专注于生物可用性,分子标和协同效应.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.7K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.7K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
Atherosclerosis III: Management
319
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
319
Venous Thrombosis III: Interprofessional Care
278
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
278
Disorders of Hemostasis
2.0K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.0K


